Thermo Fisher Scientific agreed to acquire Solventum’s purification and filtration (PF) business for approximately $4.1 billion in cash. The PF business provides purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications. The Solventum business operates globally with sites across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, and has approximately 2,500 colleagues. In 2024, Solventum’s PF business generated approximately $1 billion in revenue.
Solventum’s PF business is highly complementary to Thermo Fisher’s bioproduction business, according to Marc N. Casper, chairman, president, and CEO of Thermo Fisher. Thermo Fisher has a portfolio of offerings in cell culture media and single-use technologies and Solventum’s filtration portfolio broadens Thermo Fisher’s capabilities in the development and manufacturing of biologics, spanning upstream and downstream workflows, said Casper.
“The addition of Solventum’s business is an outstanding strategic fit with our company and will create significant value for our customers and shareholders,” added Casper. “Solventum’s portfolio of solutions will be valued by our customers, and further demonstrate our disciplined capital deployment strategy which has an excellent track record of creating shareholder value.
“As the trusted partner to our customers, Solventum’s PF business will expand and add differentiated capabilities to our bioprocessing portfolio to better serve our customers in this rapidly growing market.”
The transaction is expected to be completed by the end of 2025 and is subject to customary closing conditions and regulatory approvals. Once the transaction closes, Solventum’s PF business will become part of Thermo Fisher’s Life Sciences Solutions segment.